Can daily EGFR pills keep early lung cancer from returning after surgery?

NCT ID NCT07837739

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time

Summary

Researchers are running a registry study to watch how well EGFR tyrosine kinase inhibitor pills work after surgery in people with early-stage, EGFR-mutant non-small cell lung cancer. About 100 adults, ages 18 to 75, join across five centers, and all have tumors with an EGFR alteration and features that raise the risk of recurrence. Treatment follows routine practice rather than random assignment, so each person and their doctor decide whether to use the pills or simply monitor. The study tracks how long participants stay cancer-free, overall survival, quality of life, and side effects, and it collects tumor tissue and blood samples for genetic analysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EGFR tyrosine kinase inhibitor pills taken after lung cancer surgery, including gefitinib, erlotinib, icotinib, osimertinib, furmonertinib, and almonertinib
What this could lead to
If the approach helps, it could sharpen guidance on which early-stage EGFR-mutant lung cancers benefit from pill therapy after surgery and for how long.
What could go wrong
This registry observes routine care rather than assigning treatment, so patients who take the drugs may differ from those who do not, which can muddy comparisons. The 100-person sample is small, and follow-up must stretch years before recurrence patterns become clear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with EGFR-mutant, completely resected high-risk stage IA2 to stage IIB NSCLC/lung adenocarcinoma who are treated and followed at participating thoracic oncology centers in Hubei Province, China.

Ages

18 to 75 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-75 years, male or female, with written informed consent. * Histologically confirmed primary non-small cell lung cancer, pathologic stage IA2 to IIB; protocol summary further specifies lung adenocarcinoma / predominantly non-squamous histology. * For stage IA2 disease, at least one protocol-defined high-risk feature: invasive component \>2 cm; lymphovascular invasion; high-grade pattern comprising ≥20% solid, micropapillary, cribriform, or complex glandular components; spread through air spaces (STAS); or sublobar resection (segmentectomy/wedge resection). * EGFR mutation-positive disease confirmed by the central laboratory, including exon 19 deletion, L858R, exon 20 insertion, or PACC mutation. * Complete surgical resection with negative margins (R0); lobectomy or sublobar resection may be included according to the protocol. * No previous antitumor treatment, including no neoadjuvant radiotherapy, chemotherapy, targeted therapy, or immunotherapy. * ECOG Performance Status 0-1. * Hematologic criteria: RBC ≥3.0×10\^12/L; WBC ≥3.5×10\^9/L; ANC ≥1.5×10\^9/L; platelet count ≥100×10\^9/L; hemoglobin ≥90 g/L. * Renal function: serum creatinine ≤1.2×ULN. * Hepatic function: total bilirubin ≤1.5×ULN; ALT and AST ≤1.5×ULN. * Able and willing to comply with protocol-specified treatment/observation and follow-up. * Adequate tumor tissue available and willingness to provide tissue and blood samples for study analyses. * Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study. Exclusion Criteria: * Contraindication to anesthesia or surgery, or death attributable to the surgical procedure before study enrollment/evaluation. * Any systemic disease incompatible with participation in the clinical study or inability to provide written informed consent. * Pregnancy or breastfeeding. * Known active alcohol or drug abuse or dependence. * Any serious or unstable medical condition or psychiatric disorder that, in the investigator's judgment, would make participation inappropriate. * Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.